EpiAxis Therapeutics

What EpiAxis Therapeutics does

EpiAxis Therapeutics Pty Ltd is an Australian, privately held oncology biotechnology company developing next-generation Lysine Specific Demethylase 1 (LSD1) inhibitors intended for the treatment of aggressive solid tumours. The company's stated scientific hypothesis is that LSD1 inhibition can reverse or bypass resistance mechanisms, thereby "unlocking the power of existing therapies" and converting therapy-resistant cancers into therapy-responsive disease. The product platform is described as "next-generation LSD1 inhibitors" with a novel mechanism architecture, but the source data does not disclose named drug candidates, lead compounds, target indications, preclinical data, clinical-stage programs, or regulatory filings, so the program's actual maturity cannot be assessed from public material.

The company operates as a privately held, pre-revenue R&D entity with a 1-10 employee footprint headquartered in Australia (Canberra). Its commercial model is implicit biotech standard: future value creation is expected to flow either through out-licensing assets to larger pharmaceutical partners, executing co-development/collaboration agreements, or independently advancing candidates through clinical development and eventual commercialization via regulated distribution channels. Capital inputs to date have come from small, early-stage Australian funders (Sydney Angels in December 2020 and Artesian VC in March 2021); specific round sizes are undisclosed. The disclosed leadership consists only of CEO Jeremy Chrisp, with no scientific founders, advisory board, or R&D leadership named in the source data. No partnerships, M&A activity, patents, certifications, or awards are disclosed. The end customers, if and when commercialization occurs, would be cancer patients with aggressive solid tumours (notably those who have developed resistance to existing therapies) and the institutional payers and oncology treatment centres that serve them; downstream counterparties would be pharma licensees or acquirers.

Name

EpiAxis Therapeutics

Legal name

EpiAxis Therapeutics Pty Ltd

Website

https://epiaxistherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

EpiAxis Therapeutics is an Australian privately held biotechnology company developing next-generation LSD1 inhibitors intended to overcome therapy resistance in patients with aggressive solid tumours; the company is pre-revenue, pre-clinical, and has not disclosed named drug candidates, clinical programs, or partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Canberra

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pre-revenue stage: EpiAxis Therapeutics is an oncology biotechnology company in the research and development stage. No commercial revenue streams are currently established.

Distribution channels1 record

Marketing channels1 record

Core offering

EpiAxis Therapeutics is an Australian oncology biotechnology company developing next-generation LSD1 (Lysine Specific Demethylase 1) inhibitors — small-molecule epigenetic drug candidates — aimed at unlocking the power of existing cancer therapies for patients with aggressive solid tumours by transforming therapy resistance into responsiveness. As a pre-commercial R&D-stage company, EpiAxis has no named drug candidates or approved products publicly identified at this time and is positioned to out-license or partner its therapeutic assets.

Product overview

EpiAxis Therapeutics is an oncology biotechnology company based in Australia pioneering next-generation LSD1 inhibitors for the treatment of advanced cancers. The company is developing its LSD1 inhibition technology to unlock the power of existing therapies, targeting aggressive solid tumours with the goal of transforming resistance into responsiveness. As a clinical-stage biotechnology company, EpiAxis is focused on developing therapeutic candidates rather than software products; no named drug products, clinical candidates, or specific therapeutic programs have been publicly identified in the available source material.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights3 records

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/epiaxis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpiAxis Therapeutics